Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbhfiledCriticalMerck Patent Gmbh
Priority claimed from EP16804956.7Aexternal-prioritypatent/EP3371165B1/en
Publication of HRP20220517T1publicationCriticalpatent/HRP20220517T1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Plural Heterocyclic Compounds
(AREA)
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Claims (2)
1. 1-(4-(((6-amino-5-(4-fenoksifenil)pirimidin-4-il)amino) metil)-4-fluoropiperidin-1-il)prop-2-en-1-on (A225), i farmaceutski upotrebljive soli, uključujući njihove smjese u svim omjerima, za upotrebu u liječenju ili prevenciji mijeloproliferativnih poremećaja ili raka, pri čemu je rak odabran od ne-Hodgkinovog limfoma plaštenih stanica i ne-Hodgkinovog difuznog limfoma velikih b-stanica, uključujući podtip abc.1. 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)-4-fluoropiperidin-1-yl)prop-2-en-1-one ( A225), and pharmaceutically acceptable salts, including mixtures thereof in all proportions, for use in the treatment or prevention of myeloproliferative disorders or cancer, wherein the cancer is selected from non-Hodgkin's mantle cell lymphoma and non-Hodgkin's diffuse large b-cell lymphoma, including subtype abc.2. Spoj za upotrebu prema patentnom zahtjevu 1, i njegove farmaceutski upotrebljive soli, uključujući njihove smjese u svim omjerima, naznačen time što se spoj koristi u farmaceutskom pripravku zajedno s farmaceutski prihvatljivim nosačem.2. The compound for use according to patent claim 1, and its pharmaceutically usable salts, including their mixtures in all proportions, characterized in that the compound is used in a pharmaceutical preparation together with a pharmaceutically acceptable carrier.
HRP20220517TT2015-11-042016-11-04A btk inhibitory for use in treating cancer
HRP20220517T1
(en)
Compounds derived from thieno (3,2-d) pyrimidine, kinase inhibitors; pharmaceutical composition; and its use in the prevention or treatment of a disease related to kinases such as cancer.
Compounds derived from 7h-pyrrolo [2,3-d] pyrimidines 4- (amimo-substituted), lrrk2 inhibitors; pharmaceutical composition that includes them; and method to treat parkinson's disease.
Compounds derived from benzyl sulfonamide, mogat-2 inhibitors; crystalline compound; pharmaceutical composition; and its use in the treatment of hypertriglyceridemia.
Carbamate / urea derived compounds, histamine h3 receptor inhibitors; preparation procedure; intermediate compound; pharmaceutical composition; pharmaceutical combination; and use in the treatment of narcolepsy.
Pharmaceutical composition and pharmaceutical dosage form comprising (e) -4- (2- (aminomethyl) -3-fluoroallyloxy) -n-tert-butylbenzamide, process for its preparation, methods for treatment and uses thereof.